Lyell Immunopharma Inc Ordinary Shares LYEL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
-
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
-
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
Trading Information
- Previous Close Price
- $8.19
- Day Range
- $7.92–8.44
- 52-Week Range
- $7.20–45.00
- Bid/Ask
- $7.25 / $10.00
- Shares Outstanding
- 24.51M
- Market Cap
- $198.98M
- Volume/Avg
- 194,964 / 152,698
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5,844.36
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 161
- Website
- https://www.lyell.com
Valuation
|
Metric
|
LYEL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.75 |
Price/Sales | 5,844.36 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LYEL
|
|---|---|
Quick Ratio | 5.12 |
Current Ratio | 5.36 |
Interest Coverage | — |
Quick Ratio
LYEL
Profitability
|
Metric
|
LYEL
|
|---|---|
Return on Assets (Normalized) | −39.32% |
Return on Equity (Normalized) | −51.02% |
Return on Invested Capital (Normalized) | −47.29% |
Return on Assets
LYEL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Fx!%sd | LOCK|w&h^v | $127B | |||
| Moderna Inc
MRNA
| LOCK|gdmhBw | LOCK|HLx | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|lHsQj@ | LOCK|$<l& | $81B | |||
| argenx SE ADR
ARGX
| LOCK|CW&Gnn | LOCK|&zw | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$b&p<?! | LOCK|ll | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|cYHK&X | LOCK|c!g$$ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@tc#&N?^ | LOCK|&S>M@ | $27B | |||
| Incyte Corp
INCY
| LOCK|Q@m#?^v | LOCK|C< | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|$kSVSy | LOCK|G&< | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|p>?RyL | LOCK|t#& | $14B |
United States